A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

Trial Details

NCT ID
NCT07109726
Phase
PHASE1 / PHASE2
Sponsor
Terremoto Biosciences Inc.
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • TER-2013
  • Fulvestrant injection
Locations (sample)
  • Orlando, Florida, United States|28.53834,-81.37924
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Omaha, Nebraska, United States|41.25626,-95.94043

Key Eligibility Criteria

  • Metastatic or locally advanced, unresectable disease
  • No available treatment with curative intent
  • Presence of lesions to be evaluated per RECIST v1.1:
  • a. Dose Escalation: measurable or evaluable disease b. Cohort Expansion: measurable disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →